Contact Us
Drug Search Results
More Filters [+]

Navitoclax

Alternative Names: navitoclax, abt-263
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

Navitoclax is a BCL-XL/BCL-2 inhibitor that is being investigated to treat myelofibrosis. (Sourced from: https://www.abbvie.com/our-science/pipeline/navitoclax.html)

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Navitoclax

Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Puerto Rico, Russia, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 16

Highest Development Phases

Phase 3: Myelofibrosis

Phase 2: Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia

Phase 1: Acute Myeloid Leukemia|Myeloproliferative Disorders|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TRANSFORM-2

P3

Active, not recruiting

Myelofibrosis

2031-11-25

TRANSFORM-1

P3

Unknown status

Myelofibrosis

2029-12-20

M16-109

P2

Unknown Status

Myelofibrosis

2029-03-08

2017-001398-17

P2

Unknown status

Myelofibrosis

2027-09-04

Recent News Events

Date

Type

Title

10/01/2024

News Article

 Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer

05/14/2024

PubMed

 Advances in pharmacotherapy for myelofibrosis: what is the current state of play?

05/08/2024

PubMed

 Revealing prognostic insights of programmed cell death (PCD)-associated genes in advanced non-small cell lung cancer.

04/23/2024

PubMed

 ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models.

11/28/2023

News Article

 Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

03/10/2023

News Article

 BCL-2 (b-cell lymphoma 2) inhibitors market size to increase by USD 1,657.08 million between 2022 and 2027; Growing approval of combination therapy identified as key trend - Technavio

02/08/2023

News Article

 Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions